Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study

双盲 认知 生活质量(医疗保健) 物理疗法 临床心理学
作者
Rachelle S. Doody,Gavrilova Si,Mary Sano,Ronald G. Thomas,Paul S. Aisen,Sergey O. Bachurin,Lynn Seely,David T. Hung
出处
期刊:The Lancet [Elsevier BV]
卷期号:372 (9634): 207-215 被引量:417
标识
DOI:10.1016/s0140-6736(08)61074-0
摘要

Summary Background Although treatments for Alzheimer's disease sometimes improve cognition, functional ability, or behaviour compared with baseline levels, such improvements are inconsistent across studies and measures, and effects diminish over time. More effective treatments are needed. We assessed the safety, tolerability, and efficacy of dimebon in the treatment of patients with mild-to-moderate Alzheimer's disease. Methods We enrolled 183 patients with mild-to-moderate Alzheimer's disease (mini-mental state examination [MMSE] scores 10–24) at 11 sites in Russia. Patients were randomly assigned by a computer-generated randomisation scheme to receive oral dimebon, 20 mg three times a day (60 mg/day [n=89]), or matched placebo (n=94). Other antidementia drugs were not allowed. The primary outcome measure assessed cognition, the difference in mean change from baseline to week 26, or last completed observation on the cognitive subscale of the Alzheimer's disease assessment scale (ADAS-cog). All patients and study personnel were blinded throughout the study. We compared dimebon with placebo with an intention-to-treat analysis, with last observation carried forward (ITT-LOCF) imputation. Analyses were repeated on the fully evaluable population, defined as all patients in the intention-to-treat population who had an ADAS-cog at week 26 and at least 80% compliance. 134 patients (68 in dimebon group, 66 in placebo group) enrolled in the 6-month blinded extension phase of the study. This trial is registered with Clinicaltrials.gov, number NCT00377715. Findings 155 (85%) patients completed the trial (78 [88%] in dimebon group, 77 [82%] in placebo group). Treatment with dimebon resulted in significant benefits in ADAS-cog compared with placebo (ITT-LOCF) at week 26 (mean drug-placebo difference −4·0 [95% CI −5·73 to −2·28]; p Interpretation Dimebon was safe, well tolerated, and significantly improved the clinical course of patients with mild-to-moderate Alzheimer's disease. Funding Medivation (USA).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
上官若男应助小鞠佩奇采纳,获得10
2秒前
现代绮玉完成签到,获得积分10
2秒前
qiu发布了新的文献求助10
4秒前
枫1538完成签到,获得积分10
5秒前
疯狂的炳发布了新的文献求助10
5秒前
NexusExplorer应助U9A采纳,获得10
8秒前
wanci应助喽喽采纳,获得10
10秒前
10秒前
Newt应助明天会更好采纳,获得10
11秒前
11秒前
英俊的如霜完成签到,获得积分10
13秒前
14秒前
14秒前
15秒前
荣一完成签到,获得积分10
15秒前
16秒前
电小渣发布了新的文献求助10
16秒前
wangjustb发布了新的文献求助10
17秒前
17秒前
大力水手完成签到,获得积分10
17秒前
19秒前
小鞠佩奇发布了新的文献求助10
20秒前
21秒前
22秒前
24秒前
24秒前
24秒前
舒适绮完成签到,获得积分10
25秒前
25秒前
xiutang发布了新的文献求助30
25秒前
小鞠佩奇完成签到,获得积分10
25秒前
25秒前
27秒前
29秒前
yuwen发布了新的文献求助10
29秒前
粥粥完成签到,获得积分10
31秒前
俊俊发布了新的文献求助10
31秒前
32秒前
武1完成签到,获得积分20
33秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3967482
求助须知:如何正确求助?哪些是违规求助? 3512759
关于积分的说明 11164944
捐赠科研通 3247740
什么是DOI,文献DOI怎么找? 1794021
邀请新用户注册赠送积分活动 874785
科研通“疑难数据库(出版商)”最低求助积分说明 804517